Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Cutaneous Medicine and Surgery

30.06.2005

Canadian Practical Guide for the Treatment and Management of Atopic Dermatitis

verfasst von: Charles Lynde, Kirk Barber, Joel Claveau, David Gratton, Vincent Ho, Bernice Krafchik, Richard Langley, Danielle Marcoux, Eileen Murray, Neil Shear

Erschienen in: Journal of Cutaneous Medicine and Surgery

Einloggen, um Zugang zu erhalten

Abstract

Background

Atopic dermatitis is a common condition, with a lifetime prevalence of approximately 10% to 20% among the Canadian population. A clear, practical, Canadian guideline for the management of these patients has been lacking.

Objective

To provide primary-care physicians, pediatricians and dermatologists with the first practical and comprehensive set of Canadian recommendations for the management of atopic dermatitis.

Methods

A group of Canadian dermatologists convened to review the current issues of diagnosis, treatment and international guidelines and adapt them to the Canadian context. The reviewers used the latest clinical trial data on atopic dermatitis, complemented by clinical experience, to develop the consensus recommendations found in this review.

Results

In the present report, following a brief review of the epidemiology of and clinical diagnosis criteria for atopic dermatitis, the recommendations for treatment and management are detailed. These recommendations, which are intended to provide clinicians with a useful and valuable tool to help manage their patients with atopic dermatitis, are divided into the following sections: epidemiology, diagnosis, general measures/skin care, acute management of atopic dermatitis, long-term management/disease control, adjunct therapies, and considerations for switching between anti-inflammatory therapies/handling treatment failure.
General measures discussed include hydration with bathing and the use of moisturizers. Management strategies discussed include topical corticosteroids, topical calcineurin inhibitors, antihistamines and anti-infectives.
A management algorithm is also presented.
Literatur
1.
Ellis C, Luger T, Abeck D, et al International Consensus Conference on Atopic Dermatitis II (ICCAD II) clinical update and current treatment strategies. Br J Dermatol 2003; 148(Suppl 63):3–10PubMed
2.
Boguniewicz M, Leung D. Atopic Dermatitis. In: Middleton E, et al Allergy, Principles and Practice, 5th Ed., Mosby, St. Louis, p. 1123. 1998
3.
Hanifin JM. Epidemiology of Atopic Dermatitis. Immunol Allergy Clin NA 2002; 22:1–24
4.
Graham-Brown RA. Atopic dermatitis: predictions, expectations, and outcomes. J Am Acad Dermatol 2001; 45(1 Suppl):S61–3PubMed
5.
Leung DY. Atopic dermatitis: immunobiology and treatment with immune modulators. Clin Exp Immunol 1997; 107(Suppl 1):25–30PubMed
6.
Eczema Prevalence in Canada. Ipsos-Insight Health, 2003
7.
Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994;131(3):383–96PubMed
8.
Williams HC, Burney PG, Strachan D, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol. 1994 Sep; 131(3):397–405PubMed
9.
Williams HC, Burney PG, Pembroke AC, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131(3):406–16PubMed
10.
Correale CE, Walker C, Murphy L, et al. Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999; 60(4): 1191–8, 1209–10PubMed
11.
Bergmann RL, Edenharter G, Bergmann KE, et al. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998; 28(8):965–70PubMed
12.
Leung DY, Soter NA. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44(1 Suppl):S1–S12PubMed
13.
Hoare C, Li Wan Po A, Williams H. Systematic review of treatments for atopic eczema. Health Technol Assess 2000; 4(37):1–191
14.
Grassberger M, Baumruker T, Enz A, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141(2):264–73CrossRefPubMed
15.
Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor: of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108(2):275–80CrossRefPubMed
16.
Kapp A, Bingham A, Folster-Holst R, et al. Pimecromlimu (Elidel® SDZ ASM 981) cream 1%: a new approach to long-term management of atopic dermatitis in infants 3–23 months of age. J Eur Acad Dermatol Venereol 2001; 15(suppl.2)
17.
Harper J, Green A, Scott G, et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br J Dermatol 2001; 144(4):781–7PubMed
18.
Van Leent EJM, Graeber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Br J Dermatol 2001; 143:1–8
19.
European Study Group, Graeber M, Hedgecock S, et al. SDZ ASM 981 cream: an emerging new drug for the treatment of atopic dermatitis. J Eur Acad Dermatol Venereol 1998; 11(suppl.2):S198
20.
Van Leent EJM, Ebelin ME, Burtin P, et al. Low systemic concentrations of SDZ ASM 981 after topical treatment of extensive atopic dermatitis lesions. J Eur Acad Dermatol Venereol 1998; 11(suppl.2):133–4
21.
Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)—preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001; 20(4):233–41PubMed
22.
Billich A, Aschauer H, Stuetz A. Pimecrolimus permeates less through the skin than corticosteroids and tacrolimus. J Invest Dermatol 2002; 119:346(abstract 831)
23.
Pariser D, Paller A, Langley R, et al. Efficacy and local tolerability of pimecrolimus cream 1% in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J Invest Dermatol 2002; 119:348(Abstract 845)
24.
Ho V, Halbert A, Takaoka R, et al. Pimecrolimus (Elidel, SDZ ASM 981) Cream 1% is effective and safe in infants aged 3–23 months with atopic dermatitis. J Pediat 2003; 142:155–62PubMed
25.
Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002; 46(4):495–504CrossRefPubMed
26.
Meurer M, Folster-Holst R, Wozel G, et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology. 2002; 205(3):271–7CrossRefPubMed
27.
Wahn U, Bos JD, Goodfield M, et al. Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. Pediatrics 2002; 110:e1PubMed
28.
Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002; 110(2):277–84CrossRefPubMed
29.
Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointmen for atopic dermatitis. Lancet 1994; 344(8926):883CrossRef
30.
Ruzicka T, Bieber T, Schopf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997; 337(12):816–21CrossRefPubMed
31.
Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44(1 Suppl):S58–64PubMed
32.
Reitamo S, Wollenberg A, Schopf E, et al. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group. Arch Dermatol. 2000; 136(8):999–1006PubMed
33.
Paller AS. Use of nonsteroidal topical immunomodulators for the treatment of atopic eczema in the pediatric population. J Pediatr 2001; 138:163–8PubMed
34.
Reitamo S, Van Leent EJ, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol 2002; 109(3):539–46PubMed
35.
Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998; 111(3):396–8PubMed
36.
Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998; 102(4 Pt 1):637–44PubMed
37.
Paller A, Eichenfield LF, Leung DY, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001; 44(1 Suppl):S47–57CrossRefPubMed
38.
Hanifin J, Ho V, Kaufmann R, et al. Pimecrolimus (SDZ ASM 981) cream: Good tolerability in paediatric patients. Ann Dermatol Venereol 2002; 129:1S411
39.
Hoare C, et al. Systematic review of treatments of atopic eczema. Health Technol Assess 2000;4:1–191
40.
Berth-Jones J, et al. Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double blind, parallel group study. BMJ 2003;326:1367PubMed
41.
Hanifin J, et al. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br J Dermatol 2002; 147:528–37PubMed
42.
Van der Meer JB, et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999; 140:1114–21PubMed
43.
Kawashima M, Tango T, Noguchi T, et al. Addition of fexofenadine to a topical corticosteroid reduces the pruritus associated with atopic dermatitis in a 1-week randomized, multicentre, double-blind, placebo-controlled, parallel-group study. Br J Dermatol 2003; 148(6):1212–21PubMed
44.
Diepgen TL. Early Treatment of the Atopic Child Study Group: Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002; 13(4):278–86PubMed
45.
Munday J, Bloomfield R, Goldman M, et al. Chlorpheniramine is no more effective than placebo in relieving the symptoms of childhood atopic dermatitis with a nocturnal itching and scratching component. Dermatology 2002; 205(1):40–5PubMed
46.
Chunharas A, Wisuthsarewong W, Wananukul S, et al. Therapeutic efficacy and safety of loratadine syrup in childhood atopic dermatitis treated with mometasone furoate 0.1 per cent cream. J Med Assoc Thai 2002; 85(4):482–7PubMed
47.
Rystedt L, Stranngard IL, Strannegard O. Infections as contributing factors to atopic dermatitis. Allergy 1989; 44(suppl 9):79–83PubMed
48.
Leung DY. Atopic dermatitis and the immune system: the role of superantigens and bacteria. J Am Acad Dermatol 2001; 45(1):S13–S16PubMed
49.
Thomas KS, Armstrong S, Avery A, et al. Randomised controlled trial of short bursts of a potent topical corticosteroid versus prolonged use of a mild preparation for children with mild or moderate atopic eczema. BMJ 2002; 324(7340):768PubMed
50.
Reynolds NJ, Franklin V, Gray JC, et al. Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atopic eczema: a randomised controlled trial. Lancet 2001; 357(9273):2012–6PubMed
51.
Kuanprasert N, Herbert O, Barnetson RS. Clinical improvement and significant reduction of total serum IgE in patients suffering from severe atopic dermatitis treated with oral azathioprine. Australas J Dermatol 2002; 43(2):125–7PubMed
Metadaten
Titel
Canadian Practical Guide for the Treatment and Management of Atopic Dermatitis
verfasst von
Charles Lynde
Kirk Barber
Joel Claveau
David Gratton
Vincent Ho
Bernice Krafchik
Richard Langley
Danielle Marcoux
Eileen Murray
Neil Shear
Publikationsdatum
30.06.2005
Erschienen in
Journal of Cutaneous Medicine and Surgery
Print ISSN: 1203-4754
Elektronische ISSN: 1615-7109
DOI
https://doi.org/10.1007/s10227-005-8080-3

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise